MK-6482 show promising activity in ccRCC both as monotherapy and in combination with cabozantinib Feb. 19, 2021
U.K. clearance for first-in-human study of Avacta's FAP-activated doxorubicin prodrug AVA-6000 Feb. 18, 2021
Nektar announces new collaborations for registrational study of bempegaldesleukin in SCCHN Feb. 18, 2021
New HSP90-CDC37 protein-protein interaction inhibitors with antitumor in vitro and in vivo efficacy Feb. 18, 2021
RSS